More evidence of ubrogepant effectiveness in migraine pain

  • Dodick DW & al.
  • N Engl J Med
  • 5 Dec 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Patients who received ubrogepant for treatment of migraine had greater pain relief and decrease in the most bothersome migraine symptoms at 2 hours than those who received a placebo.

Why this matters

  • This study confirms earlier research that found ubrogepant to be effective at treating acute migraine.  

Study design

  • This randomized, double-blind, parallel-group trial evaluated the efficacy, safety, and side-effect profile of ubrogepant in patients with a history of migraine (≥1 year).
  • Treatment received: placebo (n=456), 50-mg ubrogepant (n=423), or 100-mg ubrogepant (n=448).
  • Funding: Allergan.

Key results

  • The number of participants with freedom from migraine pain at 2 hours:
    • placebo group, 11.8%;
    • 50-mg ubrogepant group, 19.2% (vs placebo; OR, 1.83; Padjusted=.002); and
    • 100-mg ubrogepant group, 21.2% (vs placebo; OR, 2.04; Padjusted<.001>
  • Absence of the most bothersome symptom at 2 hours:
    • placebo group, 27.8%;
    • 50-mg ubrogepant group, 38.6% (vs placebo; OR, 1.70; Padjusted=.002); and
    • 100-mg ubrogepant group, 37.7% (vs placebo; OR, 1.63; Padjusted=.002). 
  • Any adverse events reported:
    • placebo group, 12.8%;
    • 50-mg ubrogepant group, 9.4%; and
    • 100-mg ubrogepant group, 16.3%.
  • Most common adverse events reported within 48 hours were nausea, somnolence, and dry mouth.

Limitations

  • Limited generalizability.

Coauthored by Chitra Ravi, MPharm